Integrative Modeling of Tumor Burden and Metastatic Pattern for Guiding Anti-PD-L1 Treatment of Non–Small Cell Lung Cancer: Results From Two Randomized Studies

2020 ◽  
Author(s):  
Si-Cong Ma ◽  
Xin-Ran Tang ◽  
Xue Bai ◽  
Zhi-Jiao Duan ◽  
Jian Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Burden ◽  
Small Cell ◽  
Small Cell Lung ◽  
Metastatic Pattern ◽  
Integrative Modeling ◽  
Randomized Studies

Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non–Small-Cell Lung Cancer

2020 ◽  
Vol 21 (5) ◽  
pp. e405-e414
Author(s):  
Taichi Miyawaki ◽  
Hirotsugu Kenmotsu ◽  
Keita Mori ◽  
Eriko Miyawaki ◽  
Nobuaki Mamesaya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Tumor Burden ◽  
Small Cell ◽  
Small Cell Lung

Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma

2020 ◽  
Vol 30 (9) ◽  
pp. 5021-5028
Author(s):  
Alison Dormieux ◽  
Laura Mezquita ◽  
Paul Henry Cournede ◽  
Jordi Remon ◽  
Melodie Tazdait ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Stage Iv ◽  
Small Cell ◽  
Small Cell Lung ◽  
Metastatic Pattern

scholarly journals Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer

Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6374
Author(s):  
Raphael S. Werner ◽  
Isabelle Opitz
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Patient Selection ◽  
Cell Lung Cancer ◽  
Primary Tumor ◽  
Tumor Burden ◽  
Small Cell ◽  
Current Evidence ◽  
Molecular Characteristics ◽  
Small Cell Lung

One-fourth of all patients with metastatic non-small cell lung cancer presents with a limited number of metastases and relatively low systemic tumor burden. This oligometastatic state with limited systemic tumor burden may be associated with remarkably improved overall and progression-free survival if both primary tumor and metastases are treated radically combined with systemic therapy. This local aggressive therapy (LAT) requires a multidisciplinary approach including medical oncologists, radiation therapists, and thoracic surgeons. A surgical resection of the often advanced primary tumor should be part of the radical treatment whenever feasible. However, patient selection, timing, and a correct treatment allocation for LAT appear to be essential. In this review, we aimed to summarize and discuss the current evidence on patient selection criteria such as characteristics of the primary tumor and metastases, response to neoadjuvant or first-line treatment, molecular characteristics, mediastinal lymph node involvement, and other factors for LAT in oligometastatic NSCLC.

Sign in / Sign up

Export Citation Format

Share Document